Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (05) : 375-378     DOI: 10.3971/j.issn.1000-8578.2022.21.1427
|
Research Progress of Immune Microenvironment in Multiple Myeloma
HOU Jian, WANG Junying
Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Download: PDF(3374 KB)   ( 133 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Multiple myeloma is one type of hematological malignancy, characterized by the proliferation and accumulation of monoclonal plasma cells in bone marrow. Bone marrow microenvironment plays a key supporting role in the proliferation and survival of myeloma cells, where a large number of immune cells exist but are functionally suppressed. Based on the studies of myeloma immune microenvironment in recent years, we summarize the recent advances and existing problems in the treatment of multiple myeloma and put forward some considerations and suggestions, to provide references for researchers in this field.
Keywords Multiple myeloma      Immune microenvironment      Immunotherapy      T lymphocyte      Natural killer cells     
ZTFLH:  R733.3  
Issue Date: 17 May 2022
 Cite this article:   
HOU Jian,WANG Junying. Research Progress of Immune Microenvironment in Multiple Myeloma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 375-378.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1427
http://www.zlfzyj.com/EN/Y2022/V49/I05/375
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
HOU Jian
WANG Junying
[1] van de Donk NWCJ, Pawlyn C, Yong KL. Multiple Myeloma[J].
Lancet, 2021, 397(10272): 410-427.
[2] Moreau P. HowⅠTreat Myeloma with New Agents[J]. Blood,
2017, 130(13): 1507-1513.
[3] Shah UA, Mailankody S. Emerging Immunotherapies in Multiple
Myeloma[J]. BMJ, 2020, 370: m3176.
[4] Holthof LC, Mutis T. Challenges for Immunotherapy in Multiple
Myeloma: Bone Marrow Microenvironment-Mediated Immune
Suppression and Immune Resistance[J]. Cancers (Basel), 2020,
12(4): 998.
[5] García-Ortiz A, Rodríguez-García Y, Encinas J, et al. The Role of
Tumor Microenvironment in Multiple Myeloma Development and
Progression[J]. Cancers (Basel), 2021, 13(2): 217.
[6] Nakamura K, Smyth MJ, Martinet L. Cancer Immunoediting and
Immune Dysregulation in Multiple Myeloma[J]. Blood, 2020,
136(24): 2731-2740.
[7] Rajkumar SV, Landgren O, Mateos MV. Smoldering Multiple
Myeloma[J]. Blood, 2015, 125(20): 3069-3075.
[8] Dhodapkar MV. MGUS to Myeloma: A Mysterious Gammopathy
of Underexplored Significance[J]. Blood, 2016, 128(23):
2599-2606.
[9] Mouhieddine TH, Weeks LD, Ghobrial IM. Monoclonal
Gammopathy of Undetermined Significance[J]. Blood, 2019,
133(23): 2484-2494.
[10] Bailur JK, McCachren SS, Doxie DB, et al. Early Alterations in
Stem-like/resident T Cells, Innate and Myeloid Cells in the Bone
Marrow in Preneoplastic Gammopathy[J]. JCI Insight, 2019,
5(11): e127807.
[11] Dhodapkar MV, Dhodapkar KM. Tissue-resident Memory-like
T Cells in Tumor Immunity: Clinical implications[J]. Semin

Immunol, 2020, 49: 101415.

[12] Zelle-Rieser C, Thangavadivel S, Biedermann R, et al. T cells
in Multiple Myeloma Display Features of Exhaustion and
Senescence at the Tumor Site[J]. J Hematol Oncol, 2016, 9(1):
116.
[13] Botta C, Mendicino F, Martino EA, et al. Mechanisms of Immune
Evasion in Multiple Myeloma: Open Questions and Therapeutic
Opportunities[J]. Cancers (Basel), 2021, 13(13): 3213.
[14] Lope s R, Ca e t ano J , Fe r r e i r a B, e t al . The Immune
Microenvironment in Multiple Myeloma: Friend or Foe?[J].
Cancers (Basel), 2021, 13(4): 625.
[15] Janker L, Mayer RL, Bileck A, et al. Metabolic, Anti-apoptotic
and Immune Evasion Strategies of Primary Human Myeloma
Cells Indicate Adaptations to Hypoxia[J]. Mol Cell Proteomics,
2019, 18(5): 936-953.
[16] Wu S, Kuang H, Ke J, et al. Metabolic Reprogramming Induces
Immune Cell Dysfunction in the Tumor Microenvironment of
Multiple Myeloma[J]. Front Oncol, 2021, 10: 591342.
[17] McCachren SS, Dhodapkar KM, Dhodapkar MV. Co-evolution
of Immune Response in Multiple Myeloma: Implications for
Immune Prevention[J]. Front Immunol, 2021, 12: 632564.
[18] Tamura H, Ishibashi M, Sunakawa-Kii M, et al. PD-L1-PD-1
Pathway in the Pathophysiology of Multiple Myeloma[J]. Cancers
(Basel), 2020, 12(4): 924.
[19] Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting:
Integrating Immunity's Roles in Cancer Suppression and
Promotion[J]. Science, 2011, 331(6024): 1565-1570.
[20] Guillerey C, Ferrari de Andrade L, Vuckovic S, et al.
Immunosurveillance and Therapy of Multiple Myeloma Are
CD226 Dependent[J]. J Clin Invest, 2015, 125(5): 2077-2089.
[21] Minnie SA, Kuns RD, Gartlan KH, et al. Myeloma Escape After
Stem Cell Transplantation Is A Consequence of T-cell Exhaustion
and Is Prevented by TIGIT Blockade[J]. Blood, 2018, 132(16):
1675-1688.
[22] Goodyear OC, Pratt G, McLarnon A, et al. Differential Pattern
of CD4+ and CD8+ T-cell Immunity to MAGE-A1/A2/A3
in Patients with Monoclonal Gammopathy of Undetermined
Significance (MGUS) and Multiple Myeloma[J]. Blood, 2008,
112(8): 3362-3372.
[23] Yamamoto L, Amodio N, Gulla A, et al. Harnessing the
Immune System Against Multiple Myeloma: Challenges and
Opportunities[J]. Front Oncol, 2021, 10: 606368.
[24] van de Donk NWCJ, Usmani SZ. CD38 Antibodies in Multiple
Myeloma: Mechanisms of Action and Modes of Resistance[J].
Front Immunol, 2018, 9: 2134.
[25] Romano A, Storti P, Marchica V, et al. Mechanisms of Action of
the New Antibodies in Use in Multiple Myeloma[J]. Front Oncol,
2021, 11: 684561.
[26] Nishida H. Rapid Progress in Immunotherapies for Multiple
Myeloma: An Updated Comprehensive Review[J]. Cancers
(Basel), 2021, 13(11): 2712.
[27] Minnie SA, Hill GR. Immunotherapy of Multiple Myeloma[J]. J
Clin Invest, 2020, 130(4): 1565-1575.
[28] Sperling AS, Anderson KC. Facts and Hopes in Multiple Myeloma
Immunotherapy[J]. Clin Cancer Res, 2021, 27(16): 4468-4477.
[29] Franssen LE, Stege CAM, Zweegman S, et al. Resistance
Mechanisms Towards CD38-Directed Antibody Therapy in
Multiple Myeloma[J]. J Clin Med, 2020, 9(4):1195.
[30] D'Agostino M, Raje N. Anti-BCMA CAR T-cell Therapy in
Multiple Myeloma:Can We Do Better?[J]. Leukemia, 2020, 34(1):
21-34.
[31] Kawano Y, Roccaro AM, Ghobrial IM, et al. Multiple Myeloma
and the Immune Microenvironment[J]. Curr Cancer Drug Targets,
2017, 17(9): 806-818.
[32] Manier S, Salem KZ, Park J, et al. Genomic Complexity of
Multiple Myeloma and Its Clinical Cmplications[J]. Nat Rev Clin
Oncol, 2017, 14(2): 100-113.

Related articles from Frontiers Journals
[1] YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 886-892.
[2] YIN Zhucheng, LIANG Xinjun. Research Progress on Combined Immunotherapy for Microsatellite Stable Colorectal Cancer#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 977-981.
[3] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[4] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[5] YIN Zhucheng, LIANG Xinjun. Research Progress on Hyperthermia and Anti-Tumor Immunity[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 827-831.
[6] XIA Siyu, ZHAO Zitong, LI Li. Correlation Between STK11 Gene Mutation and Immunotherapy of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 850-854.
[7] CHEN Weichang, SHI Tongguo, ZHU Jinghan, SUN Linqing, LI Juntao. Progress on Immunotherapy of Gastrointestinal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 639-643.
[8] JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai, . Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 667-674.
[9] WU Wei, JING Doudou, CAO Li, PU Feifei, SHAO Zengwu. Current Status and Prospects of Immunotherapy for Osteosarcoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 721-726.
[10] CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 727-732.
[11] ZHANG Jianning, LIU Congwei. Progress of Novel Treatment Options for Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 505-513.
[12] SUN Junzhao, CHENG Gang, ZHANG Jianning. Advances in Treatment of Brain Metastasis from Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 522-527.
[13] ZHANG Yu, HE Kunyu, FENG Shiyu. Current Progress in Treatment of Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 528-534.
[14] LI Yuxin, JIN Feng, . Immune Checkpoint PD-1-based Mechanisms of Tumor Immune Resistance and Strategies for Re-treatment After Drug Resistance[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 546-551.
[15] . Expression of MAD2L1 in Lung Adenocarcinoma and Its Effect on Immune Microenvironment[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 586-592.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed